Computational Molecular Biology 2016, Vol.6, No.1, 1-20
15
Choudhary S., Kalita M., Fang L., Patel K.V., Tian B., Zhao Y., and Brasier A.R., 2013, Inducible Tumor Necrosis Factor (TNF) Receptor-associated Factor-1
Expression Couples the Canonical to the Non-canonical NF- B Pathway inTNF Stimulation. Journal of Biological Chemistry, 288(20): 14612–14623.
Ciechanover A., 1994, The ubiquitin-proteasome proteolytic pathway. Cell, 79(1), 13–21.
Cvek B., and Dvorak Z., 2007, Targeting of Nuclear Factor- B and Proteasome by Dithiocarbamate Complexes with Metals. Curr Pharm Des., 13(30):3155-67.
D’Acquisto F., 2002, Inhibition of Nuclear Factor Kappa B (NF-B):An Emerging Theme in Anti-Inflammatory Therapies. Molecular Interventions, 2(1): 22–35.
David Y., Ziv T., Admon A., and Navon A., 2010, The E2 Ubiquitin-conjugating Enzymes Direct Polyubiquitination to Preferred Lysines. Journal of Biological
Chemistry, 285(12): 8595–8604.
Dea E.L.O., Barken D., Peralta R.Q., Tran K.T., Werner S.L., Kearns J.D., and Hoffmann A., 2007, A homeostatic model of IκB metabolism to control
constitutive NFκB activity, Molecular Systems Biology, 3:111.
Deng M., Loughran P.A., Zhang L., Scott M.J., and Billiar T.R., 2015, Shedding of the tumor necrosis factor (TNF) receptor from the surface of hepatocytes
during sepsis limits inflammation through cGMP signaling. Science Signaling, ;8(361): ra11.
Deshaies R.J., and Joazeiro C.A. RING Domain E3 Ubiquitin Ligases. Annu Rev Biochem. 78:399-434.
Durcan T.M., and Fon E.A., 2015, The three “P”s of mitophagy: PARKIN, PINK1, and post-translational modifications. Genes and Development, 29(10):
989–999.
Eungdamrong N., 2004, Modeling Cell Signaling Networks. Biology of the Cell, 96(5): 355–362.
Fagerlund R., Behar M., Fortmann K.T., Lin Y.E., Vargas J.D., Hoffmann A., and Hoffmann A., 2015, Anatomy of a negative feedback loop : the case of IkBα. J
R Soc Interface, 12(110):0262.
Fletcher S., and Hamilton A.D., 2007, Protein-protein interaction inhibitors: small molecules from screening techniques. Current Topics in Medicinal Chemistry,
7(10): 922–7.
Fosgerau K., and Hoffmann T., 2015, Peptide therapeutics: current status and future directions. Drug Discovery Today, 20(1): 122–128.
Freemont P.S., Hanson I. M., andTrowsdale J., 1991, A novel cysteine-rich sequence motif. Cell, 64(3): 483–4.
Gilmore T.D., 2006, Introduction to NF-kappaB: players, pathways, perspectives. Oncogene, 25(51): 6680–6684.
Gilmore T.D., and Herscovitch M., 2006, Inhibitors of NFκB signaling : 785 and counting, Oncogene, 25(51):6887–6899.
Glickman M.H., and Ciechanover A., 2002, The Ubiquitin-Proteasome Proteolytic Pathway: Destruction for the Sake of Construction. Physiological Reviews,
82(2): 373–428.
Gopal Y.N.V., Chanchorn E., and Van-Dyke M.W., 2009, Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions. Molecular
Cancer Therapeutics, 8(3): 552–562.
Gstaiger M., Jordan R., Lim M., Catzavelos C., Mestan J., Slingerland J., and Krek W., 2001, Skp2 is oncogenic and overexpressed in human cancers.
Proceedings of the National Academy of Sciences, 98(9): 5043–5048.
Gu J., Nie L., Wiederschain D., and Yuan Z.M., 2001, Identification of p53 sequence elements that are required for MDM2-mediated nuclear export. Molecular
and Cellular Biology, 21(24): 8533–46.
Guo H., Callaway J.B., and Ting J.P., 2015, Inflammasomes : mechanism of action , role in disease , and therapeutics, Nat Med., 21(7): 677–687.
Herrmann J., Lerman L. O., and Lerman A., 2007, Ubiquitin and Ubiquitin-Like Proteins in Protein Regulation. Circulation Research, 100(9): 1276–1291.
Hirose K., Wakashin H., Oki M., Kagami S., Suto A., Ikeda K., and Nakajima H., 2008, GS143, an IkappaB ubiquitination inhibitor, inhibits allergic airway
inflammation in mice. Biochemical and Biophysical Research Communications, 374(3): 507–11.
Hochrainer K., Mayer H., Baranyi U., Binder B.R., Lipp J., and Kroismayr R., 2005, The human HERC family of ubiquitin ligases : novel members , genomic
